Cancer Therapy with Chimeric Antigen Receptors - A Landmark Moment for Cancer Immunotherapy

Fymat, A. L.

doi:10.15406/jcpcr.2017.08.00300

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, cancer cells can fool T-cells in two ways corresponding respectively to (a) or/ and (b) above, namely, stop producing MHC on their surfaces or display a form of co-stimulatory ligands that act as off-switches. To overcome these two eventualities, the CAR technology (see [8][9][10][11][12] has made it possible to genetically modify ("engineer") the T-cells in either of two ways so that, (a) instead of the D-(dendritic cells), the T-cells could home-in directly on antigens that may be abundant on cancer cells without necessarily being presented by the MHC molecules, or else (b) obviating altogether the need for the two-step process described earlier for attacking the cancer cells.…”

Section: Systemic Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy of Brain Cancers and Neurological Disorders

Fymat¹

2017

JCPCR

Self Cite

View full text Add to dashboard Cite

Section: Systemic Immunotherapymentioning

confidence: 99%

“…This announcement has heralded the advent of the first gene therapy in the U.S. In a separate article [12], I discuss this historic action and try to elucidate its far reaching implications in the treatments of cancer and other serious and life-threatening diseases.…”

Section: A Landmark Moment For Cancer Immunotherapy With Car T-therapymentioning

confidence: 99%

Immunotherapy of Brain Cancers and Neurological Disorders

Fymat¹

2017

JCPCR

Self Cite

View full text Add to dashboard Cite

Gene and cell therapy of human genetic diseases: Recent advances and future directions

Cetin,

Erendor,

Eksi

et al. 2024

J Cellular Molecular Medi

View full text Add to dashboard Cite

Disruptions in normal development and the emergence of health conditions often result from the malfunction of vital genes in the human body. Decades of scientific research have focused on techniques to modify or substitute defective genes with healthy alternatives, marking a new era in disease treatment, prevention and cure. Recent strides in science and technology have reshaped our understanding of disorders, medication development and treatment recommendations, with human gene and cell therapy at the forefront of this transformative shift. Its primary objective is the modification of genes or adjustment of cell behaviour for therapeutic purposes. In this review, we focus on the latest advances in gene and cell therapy for treating human genetic diseases, with a particular emphasis on FDA and EMA‐approved therapies and the evolving landscape of genome editing. We examine the current state of innovative gene editing technologies, particularly the CRISPR‐Cas systems. As we explore the progress, ethical considerations and prospects of these innovations, we gain insight into their potential to revolutionize the treatment of genetic diseases, along with a discussion of the challenges associated with their regulatory pathways. This review traces the origins and evolution of these therapies, from conceptual ideas to practical clinical applications, marking a significant milestone in the field of medical science.

show abstract

Cancer Therapy with Chimeric Antigen Receptors - A Landmark Moment for Cancer Immunotherapy

Cited by 2 publications

References 11 publications

Immunotherapy of Brain Cancers and Neurological Disorders

Immunotherapy of Brain Cancers and Neurological Disorders

Gene and cell therapy of human genetic diseases: Recent advances and future directions

Contact Info

Product

Resources

About